Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

Britain's Volex jumped over 20% on Thursday after the power and data transmission products maker reported double-digit growth in annual revenue and profit, buoyed by strong EV demand and higher North ...

Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...

New York’s legal marijuana habit is getting bigger, to the tune of $1.7 billion in sales to date since the regulated market ...

India's real estate revival has gained momentum, with large developers experiencing strong pre-sales, rising cash flows, and ...

First Advantage’s first quarter was marked by strong sales execution and successful integration of its Sterling acquisition, ...

Quest Resource’s first quarter was met with a negative market reaction, following results that fell short of Wall Street ...

Nike is still reporting declines, but it's making progress on its turnaround strategy. Its missteps have allowed competitors ...